These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9550499)

  • 1. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
    Eisenberg DA
    Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
    Jacobson TA
    Ann Intern Med; 2000 Oct; 133(7):549-54. PubMed ID: 11015169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoproteins and risk for coronary artery disease.
    Ballantyne CM
    Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling risk and new therapeutic interventions: looking ahead.
    Shepherd J
    Am J Med; 1998 Feb; 104(2A):19S-22S. PubMed ID: 9550503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
    Allison TG; Squires RW; Johnson BD; Gau GT
    Mayo Clin Proc; 1999 May; 74(5):466-73. PubMed ID: 10319076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of recent clinical trials of lipid lowering in coronary artery disease.
    Smith SC
    Am J Cardiol; 1997 Oct; 80(8B):10H-13H. PubMed ID: 9372993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factor modification: rationale for management of dyslipidemia.
    Gotto AM
    Am J Med; 1998 Feb; 104(2A):6S-8S. PubMed ID: 9550500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
    Ito MK; Delucca GM; Aldridge MA
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.